[go: up one dir, main page]

MA43600A1 - Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire - Google Patents

Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire

Info

Publication number
MA43600A1
MA43600A1 MA43600A MA43600A MA43600A1 MA 43600 A1 MA43600 A1 MA 43600A1 MA 43600 A MA43600 A MA 43600A MA 43600 A MA43600 A MA 43600A MA 43600 A1 MA43600 A1 MA 43600A1
Authority
MA
Morocco
Prior art keywords
binding molecules
trispecific
human
inflammatory molecules
relates
Prior art date
Application number
MA43600A
Other languages
English (en)
Other versions
MA43600B2 (fr
Inventor
Dmitry Valentinovich Morozov
Borisovich Andrei
Ekaterina Sergeevna Zubareva
Iakov Iurevich Ustiugov
Aleksandr Vladimirovich Karabelskii
Tatiana Veniaminovna Chernovskaya
Aleksandr Valerevich Grachev
Yury Ivanovich Basovskiy
Ekaterina Aleksandrovna Lomkova
Veronika Sergeevna Usatova
Aleksei Aleksandrovich Aleksandrov
Elena Leonidovna Morozova
Roman Alekseevich Ivanov
Pavel Andreevich Iakovlev
Galina Vladimirovna Danilova
Original Assignee
Joint Stock Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company filed Critical Joint Stock Company
Publication of MA43600A1 publication Critical patent/MA43600A1/fr
Publication of MA43600B2 publication Critical patent/MA43600B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne le domaine de la biotechnologie et propose des molécules de liaison monoclonales trispécifiques qui se lient spécifiquement à l'il-17a humaine, à l'il-17f humaine et à la molécule anti-inflammatoire (y compris fno-alpha) avec un degré d'affinité élevé. L'invention concerne des constructions d'adn qui codent pour les molécule de liaison indiquées correspondant aux vecteurs d'expression et des procédés de production ainsi que des méthodes de traitement utilisant ces molécules de liaison.
MA43600A 2016-04-29 2016-12-02 Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire MA43600B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016117140A RU2680011C2 (ru) 2016-04-29 2016-04-29 Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
PCT/RU2016/050073 WO2017188850A1 (fr) 2016-04-29 2016-12-02 Anticorps trispécifique anti il-17a, il-17f et une autre molécule anti-inflammatoire

Publications (2)

Publication Number Publication Date
MA43600A1 true MA43600A1 (fr) 2019-03-29
MA43600B2 MA43600B2 (fr) 2021-06-30

Family

ID=60160914

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43600A MA43600B2 (fr) 2016-04-29 2016-12-02 Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire

Country Status (18)

Country Link
US (1) US11453717B2 (fr)
EP (1) EP3450456A4 (fr)
JP (1) JP7104463B2 (fr)
KR (1) KR102900227B1 (fr)
CN (1) CN109641953B (fr)
AU (1) AU2016404449B2 (fr)
BR (1) BR112018072294A2 (fr)
CA (1) CA3022648A1 (fr)
CL (1) CL2018003086A1 (fr)
CR (1) CR20180557A (fr)
EC (1) ECSP18088274A (fr)
MA (1) MA43600B2 (fr)
MX (1) MX2018013262A (fr)
NI (1) NI201800110A (fr)
PH (1) PH12018550180A1 (fr)
RU (1) RU2680011C2 (fr)
WO (1) WO2017188850A1 (fr)
ZA (1) ZA201807924B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005031A (es) 2015-10-27 2018-06-13 Ucb Biopharma Sprl Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
AU2022223152A1 (en) * 2021-02-19 2023-08-31 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
WO2025238133A1 (fr) * 2024-05-17 2025-11-20 UCB Biopharma SRL Anticorps multispécifique avec spécificité de liaison pour l'il-11 et l'il-17

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US20020177188A1 (en) 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
JP2007535930A (ja) 2004-05-03 2007-12-13 シェーリング　コーポレイション 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
CN104628855A (zh) * 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
RU2015132478A (ru) * 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
RS56298B1 (sr) 2011-01-14 2017-12-29 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2013063110A1 (fr) 2011-10-24 2013-05-02 Abbvie Inc. Agents de liaison immunologique bispécifiques contre le tnf et l'il-17
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
EP3027649B1 (fr) 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Anticorps bispécifiques tnfa-il-17
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules

Also Published As

Publication number Publication date
US20210332120A1 (en) 2021-10-28
JP7104463B2 (ja) 2022-07-21
RU2016117140A (ru) 2017-11-01
JP2019518473A (ja) 2019-07-04
AU2016404449B2 (en) 2024-07-25
BR112018072294A2 (pt) 2019-02-12
ECSP18088274A (es) 2019-07-31
KR20190046716A (ko) 2019-05-07
CL2018003086A1 (es) 2019-04-26
MA43600B2 (fr) 2021-06-30
PH12018550180A1 (en) 2019-03-25
CR20180557A (es) 2019-05-08
EP3450456A4 (fr) 2020-01-01
US11453717B2 (en) 2022-09-27
WO2017188850A1 (fr) 2017-11-02
NI201800110A (es) 2019-03-29
KR102900227B1 (ko) 2025-12-17
CN109641953B (zh) 2023-02-17
AU2016404449A1 (en) 2018-12-06
EP3450456A1 (fr) 2019-03-06
MX2018013262A (es) 2019-04-22
CA3022648A1 (fr) 2017-11-02
RU2016117140A3 (fr) 2018-03-21
RU2680011C2 (ru) 2019-02-14
ZA201807924B (en) 2019-08-28
CN109641953A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
EA202192736A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с псма
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
CU24606B1 (es) Moléculas de anticuerpo que se unen a cd73
MA42743A1 (fr) Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
ATE475672T1 (de) Anti-il-23-antikörper
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43600A1 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
MX2022009379A (es) Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).
MA44227B1 (fr) Anticorps pour il-17c
CR20230488A (es) Moléculas de unión terapéuticas
PH12018500058A1 (en) Fusion molecules
EA201890983A1 (ru) Способы лечения с использованием анти-il-17a/f антител
EA202290101A1 (ru) Антитела к angpt2
EA202191761A1 (ru) Новые конъюгированные молекулы нуклеиновой кислоты и их применение
MA40086A1 (fr) Anticorps anti-vasa et leurs procédés de production et d'utilisation
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
MA40908B1 (fr) Anticorps anti-il-6 améliorés
TH182687A (th) โมเลกุลฟิวชัน